Peptomyc receives 212000 euros from the Spanish Centre for the Development of Industrial Technology (CDTI)


This latest award from the CDTI and Spanish Ministry Mineco represents […]

03 / 05 / 17|

Peptomyc receives further support from Spanish Ministry Mineco


In their latest successful application for funding, Peptomyc has earned […]

25 / 04 / 17|

Peptomyc wins Startup Slam competition at BIO-Europe Spring® Barcelona

Neruda Scott (Johnson & Johnson), Bauke Anninga (Innovation Forum), Laura Soucek (Peptomyc) and Emma Kohring (Johnson & Johnson).


Panel of expert judges selects winner from 14 short-listed European start-ups that showed greatest potential for transformative healthcare solutions

Startup Slam sponsor and co-host Johnson & Johnson Innovation recognizes high caliber of entries selected to compete for prestigious award


25 / 03 / 17|

Peptomyc is proud to join CatalonioBio


CataloniaBio is an association of companies in the health and life sciences arena […]

24 / 03 / 17|

Peptomyc receives 850K € from Spanish Mineco and European Commission joint fund


The project is financed by the Spanish Ministry of Economy […]

30 / 11 / 16|

Peptomyc wins prize at EIT Health Summit

Barcelona 23-24th November 2016
Around 350 participants from 19 countries joined […]

23 / 11 / 16|

Peptomyc completed a successful and constructive Briefing Meeting with the Innovation Task Force of the European Medicines Agency (EMA) at their headquarters in London, U.K.

Such Briefing Meetings provide a forum for early dialogue covering […]

19 / 09 / 16|

Peptomyc completes Seed Funding of €1M

Funds will help company reach preclinical validation for lead candidate in glioblastoma – an aggressive and lethal brain tumor – and in other cancer indications.


27 / 04 / 16|

Peptomyc receives a business grant from ACCIÓ

This second grant in 2 months further supports Peptomyc in its mission to bring novel Myc inhibitors closer to clinical use for cancer treatment.


22 / 03 / 16|

Peptomyc succeeds in gaining first grant funding from the European Commission

This grant represents the first big step forward for the company as it looks for further funding from investors to bring its novel Myc inhibitors closer to clinical application in cancer.


22 / 02 / 16|